News Generic Form of Copaxone, GTR, Safe and Effective, Study Confirms Generic Form of Copaxone, GTR, Safe and Effective, Study Confirms by Patricia Inacio, PhD | January 30, 2017 Share this article: Share article via email Copy article link An extension trial assessing generic glatiramer acetate (GTR) treatment in multiple sclerosis (MS) patients found that the formulation is as safe and effective as Copaxone (branded glatiramer acetate), and that switching to GTR is well-tolerated. The findingsĀ were in theĀ study, āSwitching from branded to generic glatiramer acetate: 15-month GATE trial extension results,ā published in the Multiple Sclerosis Journal. Previous trials showed that daily, subcutaneous injections of Copaxone, at a dose of 20āmg per milliliter, reduced clinical relapses and lesions in relapsing-remitting multiple sclerosis (RRMS) patients. Those resultsĀ helped the treatment receive regulatory approval (in 1996 in the U.S. and 2000 in the U.K.). More recently, the U.S.Ā Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved GTR. The EMA approved the treatment once it received data from a double-blind, placebo-controlled Phase 3 clinical trial (NCT01489254)Ā comparing GTR and Copaxone. The trial showed that, in RRMS patients, GTR was as effective, safe and well-tolerated as the branded drug. The objective of the 15-month extension trial was to assess the efficacy, safety, and tolerability of prolonged exposure to GTR. Researchers also wanted to evaluate whether switching from Copaxone to GTR would impact patientsā safety. In the initial trial, patients were randomly assigned to three treatment groups. The first group was given daily, subcutaneousĀ injections of GTR (20āmg per milliliter), while the second received 20āmg per milliliter of Copaxone. Patients in the third group received a matched placebo. In the open-label extension, everyone was given 20āmg per milliliter of GTRĀ each day for 15āmonths. Researchers evaluated theĀ treatment’s safety at months 12, 15, 18, 21, and 24. They also assessed patientsā Expanded Disability Status Scale scores, and performed magnetic resonance imaging (MRI) scans at months 12, 18, and 24. The assessment included measuring patients’ glatiramer anti-drug antibodies at baseline and months one, three, six, nine, 12, 18, and 24. The mean number of lesions detected using MRIĀ was similar at months 12, 18, and 24 inĀ the GTR and trial Copaxone patients. The change in other MRI parameters was similar as well. Also, GTR was found to be safe and effective over two years. “Moreover, the extension part of this trial … demonstrates that patients can be switched safely fromĀ (Copaxone) to generic GTR without loss of efficacy, safety, or tolerability,” the researchers wrote. “These data should help patients and prescribers to positively consider GTR as an alternative to branded GA.” Print This Page About the Author Patricia Inacio, PhD Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship. Tags Copaxone, efficacy, generic, Glatiramer acetate, relapse, RRMS
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression